Cowen and Company set a $60.00 price objective on Acorda Therapeutics, Inc. (NASDAQ:ACOR) in a research note published on Tuesday morning. The firm currently has a buy rating on the biopharmaceutical company’s stock.

A number of other research firms have also issued reports on ACOR. J P Morgan Chase & Co set a $32.00 target price on shares of Acorda Therapeutics and gave the stock a buy rating in a report on Thursday, February 9th. Cantor Fitzgerald reiterated a neutral rating on shares of Acorda Therapeutics in a report on Wednesday, December 21st. Janney Montgomery Scott started coverage on shares of Acorda Therapeutics in a report on Monday, December 19th. They set a neutral rating and a $23.00 target price on the stock. Zacks Investment Research lowered shares of Acorda Therapeutics from a buy rating to a hold rating in a report on Monday, January 23rd. Finally, Evercore ISI set a $23.00 target price on shares of Acorda Therapeutics and gave the stock a hold rating in a report on Sunday, January 8th. One analyst has rated the stock with a sell rating, five have given a hold rating and five have assigned a buy rating to the stock. The stock presently has a consensus rating of Hold and a consensus target price of $33.80.

Analyst Recommendations for Acorda Therapeutics (NASDAQ:ACOR)

Shares of Acorda Therapeutics (NASDAQ:ACOR) opened at 25.30 on Tuesday. Acorda Therapeutics has a 1-year low of $16.40 and a 1-year high of $37.36. The stock’s 50 day moving average is $21.40 and its 200 day moving average is $21.73. The firm’s market capitalization is $1.15 billion.

Acorda Therapeutics (NASDAQ:ACOR) last released its earnings results on Tuesday, February 14th. The biopharmaceutical company reported $0.05 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.11 by $0.06. The business had revenue of $140.63 million for the quarter, compared to analyst estimates of $137.90 million. Acorda Therapeutics had a negative return on equity of 1.66% and a negative net margin of 4.38%. Acorda Therapeutics’s quarterly revenue was up 2.4% compared to the same quarter last year. During the same quarter last year, the company earned $0.28 earnings per share. Equities analysts predict that Acorda Therapeutics will post $1.04 earnings per share for the current year.

This article was published by Watch List News and is the sole property of of Watch List News. If you are viewing this article on another website, it was copied illegally and republished in violation of United States & international copyright & trademark legislation. The original version of this article can be accessed at http://www.watchlistnews.com/cowen-and-company-reiterates-60-00-price-target-for-acorda-therapeutics-inc-acor/1121682.html.

In other Acorda Therapeutics news, insider Ron Cohen sold 40,172 shares of the stock in a transaction that occurred on Wednesday, December 14th. The shares were sold at an average price of $20.75, for a total value of $833,569.00. Following the sale, the insider now directly owns 519,860 shares of the company’s stock, valued at approximately $10,787,095. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Corporate insiders own 8.00% of the company’s stock.

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Teacher Retirement System of Texas increased its position in Acorda Therapeutics by 17.4% in the second quarter. Teacher Retirement System of Texas now owns 6,236 shares of the biopharmaceutical company’s stock worth $159,000 after buying an additional 925 shares during the period. Municipal Employees Retirement System of Michigan increased its position in Acorda Therapeutics by 1.6% in the third quarter. Municipal Employees Retirement System of Michigan now owns 10,220 shares of the biopharmaceutical company’s stock worth $213,000 after buying an additional 160 shares during the period. Berson & Corrado Investment Advisors LLC bought a new position in Acorda Therapeutics during the third quarter worth approximately $221,000. Aperio Group LLC bought a new position in Acorda Therapeutics during the third quarter worth approximately $262,000. Finally, SECOR Capital Advisors LP bought a new position in Acorda Therapeutics during the third quarter worth approximately $274,000.

Acorda Therapeutics Company Profile

Acorda Therapeutics, Inc is a biopharmaceutical company. The Company is engaged in the identification, development and commercialization of therapies that restore function and recovers the lives of people with neurological disorders. Its commercial products include Ampyra, Fampyra, Zanaflex Capsules and a generic version of the capsules, Zanaflex tablets and Qutenza.

5 Day Chart for NASDAQ:ACOR

Receive News & Ratings for Acorda Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acorda Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.